Biotech and pharma sponsors across Europe are facing increasing complexity in clinical development. From advanced therapies to diverse patient recruitment needs, success often depends on choosing the right partners. In this on-demand 60-minute webinar, leaders from Comac Medical and ILIFE Consulting reveal why Europe’s mid-sized CROs are uniquely positioned to deliver agility, innovation, and tailored solutions that global giants often miss.
Access the full recording and slide deck to discover how mid-sized CROs can support biotech and pharma organizations in achieving operational excellence and faster study delivery.
What You’ll Learn:
✅ Gain Regional Insights – Understand the unique advantages of conducting trials in Western and Central & Eastern Europe (CEE), with real-world data and case studies.
✅ Discover the CRO Paradox – Learn how mid-sized CROs deliver both quality and flexibility while maintaining a client-first approach.
✅ Expert Perspectives – Hear directly from senior experts with decades of global clinical research and business development experience.
✅ Actionable Takeaways – Walk away with practical insights to guide your next steps in selecting CRO partners for complex, international studies.
Meet the Speakers
Christian Buhlmann – Chief Commercial Officer, Comac Medical
A global commercial leader with expertise in business development, marketing strategy, and client relations. Christian has a proven record of driving growth and building international partnerships across Europe, Asia, and North America.
Peter Windisch – Chief Operations Officer, Comac Medical
With nearly 30 years in clinical research, Peter specializes in operational excellence and trial management. His focus is on delivering innovation, efficiency, and improved trial outcomes across complex international studies.
Tanja Ouimet – Business & Strategy Director, ILIFE Consulting
A specialist in forging innovative collaborations between CROs, biotech, and pharma. Tanja brings a forward-looking perspective on how partnerships can accelerate development and enhance trial performance.
